Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

RSS » New York Times News » NYTHealth

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

July 23, 2025

18-fda-duchenne-mediumSquareAt3X-NJMqB0-rss

 The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Elevidys, after three patients died from liver failure after taking it or a similar treatment.  

Creator: The New York Times (NYTHealth)

Source URL

Related Posts

  • One Health Insights
Health Effects of Pesticides: Risks and Safer Solutions
Health Effects of Pesticides
  • One Health Insights
Childhood Obesity Prevention: Building Healthy Futures
Childhood Obesity Prevention
  • One Health Insights
Intestinal Parasites: Risks, Transmission, and Prevention
Intestinal Parasites

Most Recent

  • Book and Article Reviews
One Health Book Review: A Comprehensive Analysis 
One Health Book Review
  • Careers
Value of MPH in One Health: Career Benefits and Impact
Value of MPH in One Health
  • Community Stories
Malaria Control Strategies: One Health in Action
Malaria Control Community Stories

Spheres of Focus

Infectious Diseases

Climate & Disasters

Food &
Water

Natural
Resources

Built
Environments

Technology & Data

Featured Posts